A Study of LY3971297 in Healthy Participants

StatusCompleted
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: details revised at 1 of 4 entries Show 4 more changesShow less
    • Trial completed
    • Final enrollment: 200 participants (planned 225)
    • Primary and study completion dates changed from estimate of Aug 2026 to Aug 18, 2026
    • Eligibility criteria expanded, about 24 words
  2. Trial status changed: Recruiting → Active, Not Recruiting
    • Site details revised at 7 of 7 sites
    v23
  3. Primary and study completion moved earlier from Sep 2026 to Aug 2026
    • Site details revised at 3 of 7 sites
    v22
  4. Site details revised at 4 of 7 sitesv21
  5. Study sites: 6 to 7v20
Show 18 earlier versionsHide 18 earlier versions
  1. Primary and study completion dates: Dec 2025 to Sep 2026
    • Site contacts updated at 2 of 6 sites
    v19
  2. 3 versions Re-verified since Sep 23, 2025, no change to tracked fieldsv16-v18
  3. Site details revised at 3 of 6 sitesv15
  4. Site details revised at 1 of 6 sitesv14
  5. Primary and study completion dates: Jun 2025 to Dec 2025v13
  6. Study sites: 5 to 6v12
  7. Study sites: 4 to 5v11
  8. Study sites: 3 to 4
    • Study title shortened, about 6 words
    • Eligibility criteria expanded, about 1 word
    v10
  9. 2 versions Re-verified since Jan 22, 2025, no change to tracked fieldsv8-v9
  10. Site contacts updated at 3 of 3 sitesv7
  11. Primary endpoints: 2 to 4v6 Show 6 more changesShow less
    • Enrollment target: 188 to 225
    • Primary and study completion dates: Feb 2025 to Jun 2025
    • Interventions: LY3971297 (Drug), Placebo (Drug) to LY3971297 (Drug), LY3971297 IV (Drug), Placebo (Drug)
    • Eligibility criteria expanded, about 184 words
    • Secondary endpoints revised (2)
    • Study arms: 6 to 8
  12. Site contacts updated at 1 of 3 sitesv5
  13. Primary completion date: Oct 2024 to Feb 2025
    • Study completion date: Dec 2024 to Feb 2025
    v4
  14. Primary completion date: Oct 2, 2024 to Oct 2024
    • Study completion date: Oct 2, 2024 to Dec 2024
    v3
  15. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Dec 4, 2023 to Dec 7, 2023
    • Site details revised at 3 of 3 sites
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
363 trials monitored
See 16 trials at risk
Obesity
3,888 trials monitored
See 157 trials at risk
Hypertension
1,933 trials monitored
See 101 trials at risk
The purpose of this study is to measure side effects of LY3971297 injection administered under the skin in healthy participants and obese participants with high blood pressure (BP). Blood tests will be performed to check how much LY3971297 gets into the bloodstream and how long it takes the body to eliminate it. This is a 7-part study. The study duration will be approximately 60 days for Parts A and F, and approximately 90 days for Parts B, C, D, E, and G.
Trial Details
NCT Number NCT06148272
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Healthy, Obesity, Hypertension
Related terms Hypertension, Obesity
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov